3H-isochromene

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 3H-isochromene
• 化学式: C₉H₈O
• 分子量: 132.16
• InChiKey: PRZZTRULFLCGBS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• [EN] DISUBTITUTED AZETIDINES, PYRROLIDINES, PIPERIDINES AND AZEPANES AS INHIBITORS OF MONOAMINE OXIDASE B FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES<br/>[FR] AZÉTIDINES, PYRROLIDINES, PIPÉRIDINES ET AZÉPANES DI-SUBSTITUÉS EN TANT QU'INHIBITEURS DE MONOAMINE OXYDASE B POUR LE TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES
  申请人：UNIV OF LJUBLJANA

  公开号：WO2018055096A1

  公开（公告）日：2018-03-29

  This invention relates to new inhibitors of MAO-Bwith the general formula I, where substituents are described in patent description. Compounds can be in the form of pure enantiomers or as racemic mixtures, or in the form of pharmaceutically acceptable salts. The present invention relates to the use of these inhibitors for the alleviation of symptoms and treatment of acute and chronic neurological disorders, cognitive and neurodegenerative diseases.

  这项发明涉及具有一般式I的新MAO-B抑制剂，其中取代基在专利描述中有描述。化合物可以是纯对映体的形式，也可以是消旋混合物的形式，或者是药用盐的形式。本发明涉及利用这些抑制剂缓解症状和治疗急性和慢性神经疾病、认知和神经退行性疾病。
• NOVEL HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
  申请人：Shionogi & Co., Ltd.

  公开号：EP2604260A1

  公开（公告）日：2013-06-19

  The present invention provides novel compounds having a P2X3 and/or P2X2/3 receptor antagonistic effect. A pharmaceutical composition having a P2X3 and/or P2X2/3 receptor antagonistic effect comprising a compound of the formula (I): wherein ring A is substituted or unsubstituted 5 to 7-membered cycloalkane, substituted or unsubstituted 5 to 7-membered cycloalkene or the like; C is a carbon atom; -X- is -N(R16)- or the like; R16 is hydrogen, substituted or unsubstituted alkyl or the like; R7 is substituted or unsubstituted 5- or 6-membered heteroaryl, substituted or unsubstituted 6 to 10 membered aryl; Q1 and Q2 are each independently a carbon atom or a nitrogen atom; -L- is -O-, -S- or the like; R6 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl or the like; R2 is hydrogen, hydroxy or the like, or its pharmaceutically acceptable salt or a solvate thereof.

  本发明提供了具有 P2X3 和/或 P2X2/3 受体拮抗作用的新型化合物。 一种具有 P2X3 和/或 P2X2/3 受体拮抗作用的药物组合物，由式（I）化合物组成： 其中 环 A 是取代或未取代的 5 至 7 元环烷烃、取代或未取代的 5 至 7 元环烯烃或类似物； C 是碳原子； -X-是-N(R16)-或类似物； R16 是氢、取代或未取代的烷基或类似物； R7 是取代或未取代的 5 或 6 元杂芳基、取代或未取代的 6 至 10 元芳基； Q1和Q2各自独立地为碳原子或氮原子； -L-是-O-、-S-或类似物； R6 是取代或未取代的环烷基、取代或未取代的环烯基或类似物； R2 是氢、羟基或类似物、 或其药学上可接受的盐或其溶液。
• PRC1 inhibitors and methods of treatment therewith
  申请人：The Regents of the University of Michigan

  公开号：US11319302B2

  公开（公告）日：2022-05-03

  Provided herein are small molecule inhibitors of Polycomb Repressive Complex 1 (PRC1) activity, and methods of use thereof for the treatment of disease, including leukemia and other cancers, as well as other diseases dependent on the activity of PRC1.

  本文提供了多聚核酸抑制复合体 1（PRC1）活性的小分子抑制剂及其用于治疗疾病的方法，包括白血病和其他癌症，以及依赖于 PRC1 活性的其他疾病。
• DISUBTITUTED AZETIDINES, PYRROLIDINES, PIPERIDINES AND AZEPANES AS INHIBITORS OF MONOAMINE OXIDASE B FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
  申请人：University of Ljubljana

  公开号：EP3426634A1

  公开（公告）日：2019-01-16
• NOVEL HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME (AS AMENDED)
  申请人：Kai Hiroyuki

  公开号：US20130225596A1

  公开（公告）日：2013-08-29

  The present invention provides novel compounds having a P2X 3 and/or P2X 2/3 receptor antagonistic effect. A pharmaceutical composition having a P2X 3 and/or P2X 2/3 receptor antagonistic effect comprising a compound of the formula (I): wherein ring A is substituted or unsubstituted 5 to 7-membered cycloalkane, substituted or unsubstituted 5 to 7-membered cycloalkene or the like; C is a carbon atom; —X— is —N(R 16 )— or the like; R 16 is hydrogen, substituted or unsubstituted alkyl or the like; R 7 is substituted or unsubstituted 5- or 6-membered heteroaryl, substituted or unsubstituted 6 to 10 membered aryl; Q 1 and Q 2 are each independently a carbon atom or a nitrogen atom; -L- is —O—, —S— or the like; R 6 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl or the like; R 2 is hydrogen, hydroxy or the like, or its pharmaceutically acceptable salt or a solvate thereof.